Halozyme Therapeutics, Inc. (HALO) Receives Average Rating of “Hold” from Brokerages

Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) have received an average recommendation of “Hold” from the nine ratings firms that are covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and three have issued a buy rating on the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $18.67.

A number of brokerages have recently weighed in on HALO. BidaskClub lowered shares of Halozyme Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, January 9th. Zacks Investment Research raised shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating and set a $19.00 price target on the stock in a report on Wednesday, September 27th. BMO Capital Markets upped their price target on shares of Halozyme Therapeutics from $15.00 to $18.00 and gave the company a “market perform” rating in a report on Wednesday, November 8th. Piper Jaffray Companies upped their price target on shares of Halozyme Therapeutics from $26.00 to $29.00 and gave the company an “overweight” rating in a report on Monday, October 16th. Finally, Canaccord Genuity upped their price target on shares of Halozyme Therapeutics from $17.00 to $19.00 and gave the company a “buy” rating in a report on Wednesday, November 8th.

Shares of Halozyme Therapeutics (NASDAQ:HALO) traded up $0.13 on Friday, hitting $17.98. 1,360,000 shares of the stock were exchanged, compared to its average volume of 1,380,000. The stock has a market capitalization of $2,550.00, a price-to-earnings ratio of -26.44 and a beta of 2.09. The company has a quick ratio of 3.37, a current ratio of 3.46 and a debt-to-equity ratio of 2.01. Halozyme Therapeutics has a 12-month low of $10.79 and a 12-month high of $21.13.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, missing analysts’ consensus estimates of $0.06 by ($0.04). The company had revenue of $63.73 million for the quarter, compared to analysts’ expectations of $58.95 million. Halozyme Therapeutics had a negative net margin of 53.17% and a negative return on equity of 892.57%. Halozyme Therapeutics’s quarterly revenue was up 100.1% compared to the same quarter last year. During the same period last year, the firm earned ($0.23) earnings per share. equities research analysts forecast that Halozyme Therapeutics will post 0.2 EPS for the current fiscal year.

A number of large investors have recently bought and sold shares of HALO. The Manufacturers Life Insurance Company boosted its holdings in Halozyme Therapeutics by 524.7% in the second quarter. The Manufacturers Life Insurance Company now owns 1,011,449 shares of the biopharmaceutical company’s stock valued at $12,968,000 after purchasing an additional 849,545 shares during the last quarter. Vanguard Group Inc. boosted its holdings in Halozyme Therapeutics by 9.5% in the second quarter. Vanguard Group Inc. now owns 9,595,212 shares of the biopharmaceutical company’s stock valued at $123,010,000 after purchasing an additional 831,654 shares during the last quarter. Senzar Asset Management LLC boosted its holdings in Halozyme Therapeutics by 17.1% in the second quarter. Senzar Asset Management LLC now owns 4,087,264 shares of the biopharmaceutical company’s stock valued at $52,399,000 after purchasing an additional 597,400 shares during the last quarter. BlackRock Inc. boosted its holdings in Halozyme Therapeutics by 4.8% in the second quarter. BlackRock Inc. now owns 11,595,500 shares of the biopharmaceutical company’s stock valued at $148,652,000 after purchasing an additional 532,658 shares during the last quarter. Finally, BB Biotech AG boosted its holdings in Halozyme Therapeutics by 6.7% in the second quarter. BB Biotech AG now owns 8,265,304 shares of the biopharmaceutical company’s stock valued at $105,961,000 after purchasing an additional 515,472 shares during the last quarter. 84.45% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION NOTICE: This news story was posted by American Banking News and is owned by of American Banking News. If you are accessing this news story on another website, it was stolen and republished in violation of US and international trademark & copyright legislation. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2018/01/19/halozyme-therapeutics-inc-halo-receives-average-rating-of-hold-from-brokerages.html.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company’s segment also includes research and development activities and product sales of Hylenex recombinant.

Analyst Recommendations for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply